Healthpeak Properties (NYSE:DOC) Azioni

Healthpeak Properties

Physicians Realty Trust

Healthpeak owns a diversified healthcare portfolio of approximately 697 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.

Jim Cramer Reacts To Friday Market Plunge And Hints At His Next Buy

Mid Cap

Media

ANET

GRAL

RBRK

SHAK

TMDX

L&#39;esperto di Mad Money si esprime: quali titoli meritano attenzione e quali no? Analisi e consigli per gli investitori.

Jim Cramer: ecco le azioni che consiglia di comprare (e da evitare)

Healthpeak Properties Inc

Dock

BEYOND MED TECHS INC by BEYOND MED TECHNOLOGIES INC.

Beyond Medical Technologies Inc

Dr. Martens PLC

DigitalOcean Holdings Inc

CloudMD Software & Services Inc Ordinary Shares

Doximity Inc

FT Vest U.S. Equity Deep Buffer ETF - October

Docusign Inc

Healthpeak Properties's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) short percent of float has risen 7.14% since its last report. The company recently reported that it has 15.83 million shares sold short, which is 3.0% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Healthpeak Properties Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743523229_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Healthpeak Properties has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Healthpeak Properties's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Healthpeak Properties's peer group average for short interest as a percentage of float is 7.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

What Does the Market Think About Healthpeak Properties?

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>), adding that he likes the <a href="https://www.benzinga.com/quote/GRAL">stock a lot.</a>
Supporting his view, Morgan Stanley analyst Tejas Savant, on March 18, raised the price target on the stock from $16 to $20.
&#8220;That' like a dice roll,&#8221; Cramer said when asked about Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>). &#8220;That's a bridge too far for me.&#8221;
On the earnings front, Turkcell, on Feb. 27, posted an FY net profit of 23.52 billion Lira versus a year-ago profit of 18.13 billion Lira.
When asked about Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), he said, &#8220;I'm going to say buy half right now, and then if it breaks down below 53, then you can buy more.&#8221;
Keefe, Bruyette &amp; Woods analyst Vasundhara Govil, on March 18, upgraded Block from Market Perform to Outperform but lowered the price target from $87 to $80.
Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is a &#8220;reasonable&#8221; REIT, Cramer said.
On Feb. 28, Scotiabank analyst Nicholas Yulico maintained Healthpeak Properties with a Sector Outperform and lowered the price target from $24 to $23.
The Mad Money host said Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is doing &#8220;very, very well.&#8221;
As per the recent news, NTT DATA partnered with Rubrik on Monday for cybersecurity ransomware protection.
Cramer said Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is a hold and prefers Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) to Edwards Lifesciences.
On the earnings front, Edwards Lifesciences, on Feb. 11, posted better-than-expected quarterly earnings.
&#8220;We have to wait another quarter,&#8221; Cramer said when asked about Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>).
Wells Fargo analyst Anthony Trainor, on Wednesday, initiated coverage on Shake Shack with an Equal-Weight rating and announced a price target of $95.
TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is an &#8220;interesting&#8221; company, Cramer said. &#8220;I'm not going to necessarily recommend it right here.&#8221;
Needham analyst Mike Matson reiterated TransMedics Group with a Hold rating on Wednesday.
&#8220;It's never been this cheap that I can recall,&#8221; Cramer said when asked about Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;Here's the problem, it's a data center stock.&#8221;
On March 5, UBS analyst David Vogt upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
Turkcell Iletisim Hizmetleri shares fell 2.3% to settle at $6.08 on Thursday.
GRAIL shares gained 0.7% to close at $28.58 during the session.
Arista Networks&#8217; shares fell 3.3% to settle at $78.96.
Shake Shack shares rose 0.3% to settle at $93.62.
TransMedics Group shares gained 0.2% to close at $70.44.
Rubrik shares fell 3.8% to settle at $66.00.
Edwards Lifesciences&#8217; shares rose 0.1% to close at $71.19.
Block shares fell 3.5% to settle at $56.99 on Thursday.
Healthpeak Properties shares fell 0.4% to close at $20.22.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44534563/netflix-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades">Netflix, Vertex Pharmaceuticals And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock

Scotiabank analyst Nicholas Yulico maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Sector Outperform and lowers the price target from $24 to $23.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Healthpeak Properties, Lowers Price Target to $23

In the last three months, 4 analysts have published ratings on Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $23.5, a high estimate of $24.00, and a low estimate of $22.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.0%. 
<img src="https://www.benzinga.com/files/images/story/2025/1739563249_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Healthpeak Properties among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Amanda Sweitzer</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Healthpeak Properties. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Healthpeak Properties's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Healthpeak Properties's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Healthpeak Properties analyst ratings.</a>
<h2>All You Need to Know About Healthpeak Properties</h2>
Healthpeak owns a diversified healthcare portfolio of approximately 672 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
<h3>Healthpeak Properties's Financial Performance</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Challenges: Healthpeak Properties's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -0.34%. This indicates a decrease in top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Healthpeak Properties's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.63%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Healthpeak Properties's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 0.05%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Healthpeak Properties's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.02% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.07.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Healthpeak Properties Stock: Analyst Perspectives (4 Ratings)

Wedbush analyst Richard Anderson maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $27 to $24.

Wedbush Maintains Outperform on Healthpeak Properties, Lowers Price Target to $24

Baird analyst Amanda Sweitzer maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $25 to $24.

Baird Maintains Outperform on Healthpeak Properties, Lowers Price Target to $24

The change from a quarterly dividend to a monthly dividend provides investors with reliable monthly payments while more closely aligning with the timing of the Company's rental receipts. Future dividends are at the discretion of Healthpeak's Board of Directors.

Dividends

Healthpeak's Board Plans To Authorize Monthly Dividend Of Approximately $0.10167 Per Share Beginning April 2025

Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) just disclosed its Q4 earnings on Monday, February 3, 2025 at 04:15 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Healthpeak Properties beat estimated earnings by 2.0%, reporting an EPS of $0.46 versus an estimate of $0.45.
Revenue was up $562.52 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.01 in the last quarter, resulting in a 3.0% drop share price change the following day.
Here's a look at Healthpeak Properties's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.44</td>
<td>0.44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.45</td>
<td>0.45</td>
<td>0.45</td>
<td>0.26</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>688.98M</td>
<td>660.55M</td>
<td>588.28M</td>
<td>139.39M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>700.40M</td>
<td>695.50M</td>
<td>606.56M</td>
<td>135.47M</td>
</tr>
</tbody>
</table>

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Guidance</h3>
Healthpeak Properties management provided guidance for FY 2025, expecting earnings between $1.81 and $1.87 per share.
To track all earnings releases for Healthpeak Properties <a href="https://www.benzinga.com/quote/DOC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Breakdown: Healthpeak Properties Q4

The first quarter dividend is payable on February 26, 2025, to stockholders of record as of the close of business on February 14, 2025.
 &nbsp;

Healthpeak Properties Raises Quarterly Common Stock Cash Dividend By 1.7% From $0.30 To $0.305 Per Share

Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.45 by 2.22 percent. The company reported quarterly sales of $697.99 million which beat the analyst consensus estimate of $688.46 million by 1.38 percent. This is a 26.07 percent increase over sales of $553.65 million the same period last year.

Earnings Beats

Healthpeak Properties Q4 2024 FFO As Adjusted $0.46 Beats $0.45 Estimate, Sales $697.99M Beat $688.46M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) is projected to report quarterly earnings at $0.88 per share on revenue of $13.46 billion. 
• Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) is projected to report quarterly earnings at $2.77 per share on revenue of $780.35 million. 
• Alliance Res Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARLP#NASDAQ">ARLP</a>) is likely to report quarterly earnings at $0.67 per share on revenue of $635.60 million. 
• Johnson Outdoors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOUT#NASDAQ">JOUT</a>) is estimated to report quarterly loss at $1.30 per share on revenue of $104.73 million. 
• Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) is estimated to report quarterly loss at $0.37 per share on revenue of $373.85 million. 
• NAPCO Security Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $49.88 million. 
• Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) is expected to report quarterly loss at $0.63 per share on revenue of $86.95 million. 
• IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is estimated to report quarterly earnings at $2.40 per share on revenue of $936.68 million. 
<h3>Companies Reporting After The Bell</h3>
• BellRing Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) is expected to report quarterly earnings at $0.48 per share on revenue of $524.74 million. 
• New Jersey Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NJR#NYSE">NJR</a>) is estimated to report quarterly earnings at $1.06 per share on revenue of $468.00 million. 
• Cabot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBT#NYSE">CBT</a>) is likely to report quarterly earnings at $1.77 per share on revenue of $997.10 million. 
• KKR Real Estate Finance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is likely to report quarterly loss at $0.07 per share on revenue of $34.78 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $2.49 per share on revenue of $813.57 million. 
• Kyndryl Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) is expected to report quarterly earnings at $0.41 per share on revenue of $3.81 billion. 
• Everest Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EG#NYSE">EG</a>) is estimated to report quarterly loss at $17.08 per share on revenue of $3.93 billion. 
• Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) is likely to report quarterly earnings at $1.00 per share on revenue of $754.93 million. 
• Clorox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) is likely to report quarterly earnings at $1.40 per share on revenue of $1.63 billion. 
• J&amp;J Snack Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JJSF#NASDAQ">JJSF</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $360.85 million. 
• Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $691.84 million. 
• Palantir Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is expected to report quarterly earnings at $0.11 per share on revenue of $775.91 million. 
• MGIC Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTG#NYSE">MTG</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $303.53 million. 
• AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) is estimated to report quarterly earnings at $1.10 per share on revenue of $4.11 billion. 
• Capital Southwest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSWC#NASDAQ">CSWC</a>) is likely to report quarterly earnings at $0.62 per share on revenue of $50.62 million. 
• Woodward (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is estimated to report quarterly earnings at $1.18 per share on revenue of $772.98 million. 
• Sun Country Airlines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $258.04 million. 
• Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $104.61 million. 
• RBB Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBB#NASDAQ">RBB</a>) is expected to report quarterly earnings at $0.36 per share on revenue of $28.12 million. 
• NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) is likely to report quarterly earnings at $3.13 per share on revenue of $3.10 billion. 
• Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) is projected to report quarterly earnings at $0.59 per share on revenue of $341.43 million. 
• Rambus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) is expected to report quarterly earnings at $0.47 per share on revenue of $160.29 million. 
• NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) is estimated to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARLP

BRBR

CSWC

FLXS

IDXX

JJSF

JOUT

KFRC

KREF

LVRO

NSSC

NXPI

PLTR

RMBS

SAIA

SNCY

TWST

Earnings Scheduled For February 3, 2025

Wells Fargo analyst Connor Siversky maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Equal-Weight and lowers the price target from $23 to $22.

Wells Fargo Maintains Equal-Weight on Healthpeak Properties, Lowers Price Target to $22

Across the recent three months, 7 analysts have shared their insights on Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $25.14, a high estimate of $28.00, and a low estimate of $23.00. This upward trend is evident, with the current average reflecting a 7.3% increase from the previous average price target of $23.43.
<img src="https://www.benzinga.com/files/images/story/2024/1733410811_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Healthpeak Properties among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Amanda Sweitzer</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Connor Siversky</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>James Kammert</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$26.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Healthpeak Properties. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Healthpeak Properties compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Healthpeak Properties's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Healthpeak Properties analyst ratings.</a>
<h2>All You Need to Know About Healthpeak Properties</h2>
Healthpeak owns a diversified healthcare portfolio of approximately 672 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
<h3>Healthpeak Properties: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Healthpeak Properties's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 24.54%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Healthpeak Properties's net margin is impressive, surpassing industry averages. With a net margin of 12.49%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Healthpeak Properties's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.99%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.43%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.04.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Healthpeak Properties

Mizuho analyst Vikram Malhotra maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and lowers the price target from $25 to $24.

Mizuho Maintains Outperform on Healthpeak Properties, Lowers Price Target to $24

In the current session, the stock is trading at $22.35, after a 0.49% spike. Over the past month, Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) stock increased by 2.58%, and in the past year, by 20.41%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732885258_0.png" alt="Past Year Chart" />

<h3>Healthpeak Properties P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 44.45 in the Helath Care REITs industry, Healthpeak Properties Inc. has a higher P/E ratio of 45.39. Shareholders might be inclined to think that Healthpeak Properties Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732885258_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Healthpeak Properties

For income-focused investors, <a href="https://www.benzinga.com/real-estate/reit">real estate investment trusts (REITs)</a> are a goldmine, offering steady dividends backed by tangible assets. 
Our search for top REITs focused on large-cap stocks from the S&amp;P 500 index with a dividend yield exceeding 5% and Wall Street analysts rating them a "Buy" or higher. This rigorous filter led us to three standout picks that combine high yield with growth potential. From healthcare facilities to retail and casinos, these REITs provide both robust income and diversified exposure.
<h2 class="wp-block-heading">1. Healthpeak Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>): A Prescription For Income</h2>
Dividend Yield: 5.40% Market Cap: $15.81 billion Sector: Healthcare Facilities
Healthpeak Properties is a healthcare-focused REIT with a flair for stability and growth. Offering a 5.40% dividend yield, DOC has seen a stellar 30.67% performance over the past year and 12.32% year-to-date gains. Its price-to-free-cash-flow (P/FCF) ratio of 18.41 signals a fair valuation, making it an attractive choice for yield-seeking investors.
With the healthcare sector&#8217;s resilience, Healthpeak benefits from long-term demographic trends like aging populations, positioning itself as a dependable dividend payer in a defensive industry.
Read Also: <a href="https://www.benzinga.com/real-estate/reit/24/11/42068836/crowdstreets-new-ceo-john-imbriglia-charts-a-bold-path-for-commercial-real-estate-investors">CrowdStreet&#8217;s New CEO John Imbriglia Charts a Bold Path for Commercial Real Estate Investors</a>
<h2 class="wp-block-heading">2. Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>): The Monthly Dividend Machine</h2>
Dividend Yield: 5.37% Market Cap: $51.55 billion Sector: Retail
Nicknamed "The Monthly Dividend Company," Realty Income is a household name in income investing. Offering a 5.37% yield, O maintains a strong foothold in retail real estate, with a portfolio diversified across industries and tenants. Despite modest performance year-to-date (1.57%), its P/FCF of 15.84 underscores solid fundamentals.
Realty Income's consistent payouts and reputation for reliable income make it a cornerstone for dividend-focused portfolios. Whether the market&#8217;s hot or cold, this REIT remains a fan favorite for its unwavering commitment to shareholder returns.
<h2 class="wp-block-heading">3. VICI Properties Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VICI#NYSE">VICI</a>): A Jackpot For Investors</h2>
Dividend Yield: 5.20% Market Cap: $34.60 billion Sector: Diversified
VICI Properties owns an enviable portfolio of casino and gaming assets, including Las Vegas landmarks. Its 5.20% dividend yield is paired with a P/FCF of 15.01, making it the most attractively valued among our picks. Over the past six months, VICI has outperformed with a 16.18% gain, outpacing broader market indices.
As the gaming industry recovers post-pandemic, VICI is well-positioned to capture growth while rewarding investors with consistent income. With its diversified exposure and high yield, this REIT is a safe bet for any portfolio.
These REITs—Healthpeak, Realty Income, and VICI Properties—combine strong dividend yields with promising growth, backed by Wall Street's confidence. 
Whether you're looking for healthcare stability, retail reliability, or a gamble on casinos, these large-cap REITs deliver income with the potential for capital appreciation. For investors, the choice is clear: when it comes to dividends, these are the real estate crown jewels.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/real-estate/reit/24/11/42044923/goldman-sachs-turns-bearish-on-redfin-affordability-could-weigh-on-a-housing-recovery">Goldman Sachs Turns Bearish On Redfin: &#8216;Affordability Could Weigh On A Housing Recovery&#8217;</a></li>
</ul>

REIT

Real Estate

VICI

High-Yield REITs To Watch: Three Wall Street-Approved S&P 500 Gems

Guidance

Healthpeak Properties Raises FY24 AFFO From $1.56-$1.58 To $1.57-$1.59

RBC Capital analyst Michael Carroll maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $25 to $26.

RBC Capital Maintains Outperform on Healthpeak Properties, Raises Price Target to $26

Baird analyst Amanda Sweitzer maintains Healthpeak Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) with a Outperform and raises the price target from $24 to $25.

Comments

Healthpeak Properties

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO